First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam - Report - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Real-World Outcomes of First-Line CDK4/6 Inhibitor Therapy in HR-Positive, HER2-Negative Metastatic Breast Cancer: Insights from Ho Chi Minh City Oncology Hospital, Vietnam
Clinical Report: Real-World Outcomes of First-Line CDK4/6 Inhibitor Therapy
Overview
This study evaluates the effectiveness and safety of first-line CDK4/6 inhibitors combined with endocrine therapy in Vietnamese patients with HR-positive, HER2-negative metastatic breast cancer.
Background
Breast cancer remains the most commonly diagnosed malignancy among women globally, with HR-positive, HER2-negative subtype being the most prevalent. The introduction of CDK4/6 inhibitors has changed treatment approaches for patients with advanced disease.
Data Highlights
Outcome
Value
Median PFS
28.0 months
PFS at 12 months
66.4% (95% CI, 56.6%–74.4%)
PFS at 24 months
54.1% (95% CI, 44.2%–63.0%)
OS at 12 months
88.8%
OS at 24 months
87.8%
Grade 3–4 neutropenia
58.8%
Key Findings
Median progression-free survival (PFS) was 28.0 months.
12-month PFS rate was 66.4% and 24-month PFS rate was 54.1%.
Overall survival (OS) rates at 12 and 24 months were 88.8% and 87.8%, respectively.
ER and PR expression levels were independent prognostic factors for PFS.
58.8% of patients experienced grade 3–4 neutropenia, managed with dose adjustments.
No cases of febrile neutropenia were reported.
Clinical Implications
Clinicians should be aware of the potential for significant neutropenia and manage accordingly.
Conclusion
The findings from this study demonstrate the efficacy and safety of CDK4/6 inhibitors in a real-world setting.
